156 related articles for article (PubMed ID: 8330470)
1. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis.
Schwartz S; Brater DC; Pound D; Green PK; Kramer WG; Rudy D
Clin Pharmacol Ther; 1993 Jul; 54(1):90-7. PubMed ID: 8330470
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency.
Gehr TW; Rudy DW; Matzke GR; Kramer WG; Sica DA; Brater DC
Clin Pharmacol Ther; 1994 Jul; 56(1):31-8. PubMed ID: 8033492
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
[TBL] [Abstract][Full Text] [Related]
4. A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis.
Applefeld JJ; Kasmer RJ; Hak LJ; Dukes GE; Wermeling DP; McClain CJ
Aliment Pharmacol Ther; 1994 Aug; 8(4):397-402. PubMed ID: 7986964
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
Gentilini P; La Villa G; Marra F; Carloni V; Melani L; Foschi M; Cotrozzi G; Quartini M; Chibbaro G; Tommasi AC; Bernareggi A; Simoni A; Buzzelli G; Laffi G
J Hepatol; 1996 Oct; 25(4):481-90. PubMed ID: 8912147
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses.
Agne GF; Jung SW; Wooldridge AA; Duran SH; Ravis W; Toribio R
J Vet Intern Med; 2018 Jul; 32(4):1428-1435. PubMed ID: 29770976
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency--preliminary evaluation.
Brater DC; Rudy DR; Voelker JR; Greene PK; Gehr T; Sica DA
Cardiovasc Drugs Ther; 1993 Jan; 7 Suppl 1():69-73. PubMed ID: 8435379
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of torasemide in health and disease.
Brater DC
J Cardiovasc Pharmacol; 1993; 22 Suppl 3():S24-31. PubMed ID: 7506334
[TBL] [Abstract][Full Text] [Related]
9. The pharmacodynamics of torsemide in patients with congestive heart failure.
Vargo D; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
Clin Pharmacol Ther; 1994 Jul; 56(1):48-54. PubMed ID: 8033494
[TBL] [Abstract][Full Text] [Related]
10. Torsemide: a pyridine-sulfonylurea loop diuretic.
Blose JS; Adams KF; Patterson JH
Ann Pharmacother; 1995 Apr; 29(4):396-402. PubMed ID: 7633019
[TBL] [Abstract][Full Text] [Related]
11. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency.
Rudy DW; Gehr TW; Matzke GR; Kramer WG; Sica DA; Brater DC
Clin Pharmacol Ther; 1994 Jul; 56(1):39-47. PubMed ID: 8033493
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites.
Abecasis R; Guevara M; Miguez C; Cobas S; Terg R
Scand J Gastroenterol; 2001 Mar; 36(3):309-13. PubMed ID: 11305520
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
Lesne M
Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure.
Kramer WG; Smith WB; Ferguson J; Serpas T; Grant AG; Black PK; Brater DC
J Clin Pharmacol; 1996 Mar; 36(3):265-70. PubMed ID: 8690821
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
[TBL] [Abstract][Full Text] [Related]
16. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial.
Gerbes AL; Bertheau-Reitha U; Falkner C; Jüngst D; Paumgartner G
J Hepatol; 1993 Mar; 17(3):353-8. PubMed ID: 8315263
[TBL] [Abstract][Full Text] [Related]
17. Torasemide in the treatment of patients with cirrhosis and ascites.
Gentilini P; Laffi G; La Villa G; Carloni V; Foschi M; Romanelli RG; Marra F
Cardiovasc Drugs Ther; 1993 Jan; 7 Suppl 1():81-5. PubMed ID: 8435382
[TBL] [Abstract][Full Text] [Related]
18. Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.
Kim HO; Lee KE; Park HY; Lee NR; Oh BR; Chang BC; Gwak HS
J Pharm Pharmacol; 2013 Aug; 65(8):1195-203. PubMed ID: 23837587
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure.
Bleske BE; Welage LS; Kramer WG; Nicklas JM
J Clin Pharmacol; 1998 Aug; 38(8):708-14. PubMed ID: 9725546
[TBL] [Abstract][Full Text] [Related]
20. Furosemide kinetics and dynamics in patients with cirrhosis.
Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
